References

  1. SANCUSO [package insert]. Bedminster, NJ: ProStrakan, Inc; 2008.
  2. Data on file. ProStrakan, Inc.
  3. Shih V, Wan HS, Chan A. Clinical predictions of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother. 2009;43:444-452.
  4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. V.4.2009. http://www.nccn.org/professionals/physician_ gls/PDF/antiemesis.pdf. Accessed December 3, 2009.
  5. American Cancer Society. Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society; 2009.
  6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and neck cancers. V.1.2009. http://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf. Accessed December 3, 2009.
  7. McGettigan S, Stricker CT. Managing mucositis in head and neck cancer patients undergoing radiation therapy. Commun Oncol. 2006;3(6):653-656.
  8. Treister NS, Woo S-B. Chemotherapy-induced oral mucositis. http://emedicine.medscape.com/article/1079570-overview. Accessed December 3, 2009.
  9. Postma TJ, Vermorken JB, Liefting AJM, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy.
    Ann Oncol. 1995;6(5):489-494.
  10. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999;4(3):191-196.
  11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric cancer. V.1.2010. http://www.nccn.org/professionals/physician_gls/PDF/gastric.pdf. Accessed December 3, 2009.
  12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast cancer. V.1.2010. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed December 3, 2009.
  13. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J. 2008;14(2):85-93.
  14. Booth CM, Clemons M, Dranitsaris G, et al. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol. 2007;5(8):374-380.
  15. Hassett MJ, O’Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98(16):1108-1117.
  16. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cervical cancers. V.1.2010. http://www.nccn.org/professionals/physician_gls/PDF/cervical.pdf. Accessed December 3, 2009.
  17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian cancer: Including fallopian tube cancer and primary peritoneal cancer V.2.2009. http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf. Accessed December 3, 2009.
  18. Winkeljohn DL. Oral chemotherapy medications: the need for a nurse’s touch. Clin J Oncol Nurs. 2007;11(6):793-796.
  19. Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56(16):286-290.
  20. Hauser K, Walsh D, Rybicki LA, Davis MP, Seyidova-Khoshknabi D. Fatigue in advanced cancer:
    a prospective study. Am J Hosp Palliat Care. 2008;25(5):372-378.